Chenwen Cai

Chenwen Cai

Auto-generated profile, based on publicly available information

Chenwen Cai

Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine;Shanghai Key Laboratory of Biliary Tract Disease Research;Shanghai Research Center of Biliary Tract Disease;Institute of Biliary Tract Disease, Shanghai Jiao Tong University School of Medicine,Shanghai 200092, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2022 in Intestinal Research
Verified
Journal Article
Open access
PDF file
CCChenwen Cai
Chenwen Cai
JLJuntao Lu
Juntao Lu
LLLijie Lai
Lijie Lai
DSDongjuan Song
Dongjuan Song
JSJun Shen
Jun Shen
ZRZhihua Ran
Zhihua Ran
Background/Aims: The incidence and prevalence of inflammatory bowel disease (IBD) is rising in Asia recently. The study aimed to obtain a comprehensive understanding of the current status of drug therapy and monitoring for IBD in Asia.Methods: A questionnaire investigation on drug therapy and monitoring for IBD was conducted right before the 6th Annual Meeting of Asian Organization for Crohn’s & Colitis. Questionnaires were provided to Asian physicians to fill out via emails between March and May 2018.Results: In total, responses of 166 physicians from 129 medical centers were included for analysis. Among the surveyed regions, the most average number of IBD specialist gastroenterologists and nurses was 4.8 per center in Taiwan and 2.5 per center in Mainland China, respectively. 5-Aminosalicylic acid/sulfasalazine (99.4%) was the most preferred first-line choice for mild-moderate ulcerative colitis (UC), meanwhile corticosteroid (83.7%) was widely applied for severe UC. The first-line medication for Crohn’s disease (CD) markedly varied as corticosteroid (68.1%) was the most favored in Mainland China, Japan, and South Korea, followed by infliximab (52.4%) and azathioprine (47.0%). Step-up strategy was preferred in mild-moderate UC (96.4%), while 51.8% of the physicians selected top-down treatment for CD. Only 25.9% and 17.5% of the physicians could test blood concentration of infliximab and antibody to infliximab in their hospitals, respectively.Conclusions: The current status of drug therapy and monitoring for IBD in Asia possesses commonalities as well as differences. Asian recommendations, IBD specialist teams and practice of therapeutic drug monitoring are required to improve IBD management in Asia.

1 June 2021 in iScience
Verified
Journal Article
Open access
CCChenwen Cai
Chenwen Cai
SZSibo Zhu
Sibo Zhu
JTJinlu Tong
Jinlu Tong
TWTianrong Wang
Tianrong Wang
QFQi Feng
Qi Feng
JSJun Shen
Jun Shen
Management of terminal ileal Crohn disease (CD) is difficult due to fibrotic prognosis and failure to achieve mucosal healing. A limited number of synchronous analyses have been conducted on the transcriptome and microbiome in unpaired terminal ileum tissues. Therefore, our study focused on the transcriptome and mucosal microbiome in terminal ileal tissues of patients with CD with the aim of determining the role of cross-talk between the microbiome and transcriptome in the pathogenesis of terminal ileal CD. Mucosa-attached microbial communities were significantly associated with segmental inflammation status. Interaction-related transcription factors (TFs) are the panel nodes for cross-talk between the gene patterns and microbiome for terminal ileal CD. The transcriptome and microbiome in terminal ileal CD can be differently related to the local inflammatory status, and specific differentially expressed genes may be targeted for mucosal healing. TFs connect gene patterns with the microbiome by reflecting environmental stimuli and signals from microbiota.

28 June 2022 in Zhonghua Wai Ke Za Zhi [chinese Journal of Surgery]
Verified
Journal Article
Closed access
ZYZ Y Yang
Z Y Yang
SLS L Liu
S L Liu
CCC Cai
C Cai
ZWZ Y Wu
Z Y Wu
YXY C Xiong
Y C Xiong
WGWei Gong
Wei Gong
Due to the lack of effective early diagnosis and treatment, gallbladder cancer(GBC) remains a malignant tumor with extremely high malignancy and poor prognosis. Therefore, high quality studies are required to break through the bottleneck in GBC diagnosis and treatment. This article reviewed the domestic and foreign GBC research published in 2021, presenting a comprehensive summary of the important advances in the field of clinical diagnosis and treatment. Latest epidemiological data and risk factors, emerging diagnostic methods of peripheral blood laboratory tests and imaging, new pathologic classification system, hot topics and controversies of surgical treatment as well as the dynamics of systemic treatment of GBC are reviewed in the article. The present findings may contribute to a more efficient means of diagnosis and treatment for GBC and hold the promise of improved outcomes for patients with GBC.